Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

AML - 1478

Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

Akshay Aluri

Poster Presenter: Akshay Aluri

Thumbnail for Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

AML - 1483

Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML

Paloma Resende

Poster Presenter: Paloma Resende

Thumbnail for Temporal Decline in Early Mortality in Acute Myeloid Leukemia Across Chemotherapy, Hypomethylating Agent, and Venetoclax-Based Therapeutic Eras: A Four-Decade Population-Based Analysis

AML - 1492

Temporal Decline in Early Mortality in Acute Myeloid Leukemia Across Chemotherapy, Hypomethylating Agent, and Venetoclax-Based Therapeutic Eras: A Four-Decade Population-Based Analysis

Shahzaib Maqbool

Poster Presenter: Shahzaib Maqbool

Thumbnail for CRISPR/Cas9-Mediated SHP2 Knockout in Jurkat T Cells Using Neon and MaxCyte Electroporation Platforms: Establishment and Validation of a Model for SHP2-Driven Resistance Mechanisms

AML - 150

CRISPR/Cas9-Mediated SHP2 Knockout in Jurkat T Cells Using Neon and MaxCyte Electroporation Platforms: Establishment and Validation of a Model for SHP2-Driven Resistance Mechanisms

Kashif Ali

Poster Presenter: Kashif Ali

Thumbnail for Age-, Sex-, Race-, and Ethnicity-Dependent Architecture of the AML DriverMutational Landscape: A Real-World Analysis of 5,111 Patients in AACRProject GENIE v18.0

AML - 1509

Age-, Sex-, Race-, and Ethnicity-Dependent Architecture of the AML DriverMutational Landscape: A Real-World Analysis of 5,111 Patients in AACRProject GENIE v18.0

Nency Ganatra

Poster Presenter: Nency Ganatra

Thumbnail for Disseminated Intravascular Coagulation in Adults with Active Acute Promyelocytic Leukemia: A Nationwide Analysis of Demographics, Comorbidities, Complications, and 30-Day Readmission Rates

AML - 1521

Disseminated Intravascular Coagulation in Adults with Active Acute Promyelocytic Leukemia: A Nationwide Analysis of Demographics, Comorbidities, Complications, and 30-Day Readmission Rates

Aishwarya Ramesh

Poster Presenter: Aishwarya Ramesh

Thumbnail for Temporal Changes in AML Survival Across Treatment Eras: A SEER Database Analysis (2000-2022)

AML - 1526

Temporal Changes in AML Survival Across Treatment Eras: A SEER Database Analysis (2000-2022)

Maryam Ali

Poster Presenter: Maryam Ali

Thumbnail for Higher ASXL1 Expression Is Associated With Improved Overall Survival in TP53-Mutated Acute Myeloid Leukemia

AML - 1534

Higher ASXL1 Expression Is Associated With Improved Overall Survival in TP53-Mutated Acute Myeloid Leukemia

Max Bustillo

Poster Presenter: Max Bustillo

Thumbnail for Transfusion Patterns and Clinical Characteristics According to Treatment Strategy in Acute Myeloid Leukemia: A 5-Year Experience at a National Referral Oncology Center in Mexico

AML - 1536

Transfusion Patterns and Clinical Characteristics According to Treatment Strategy in Acute Myeloid Leukemia: A 5-Year Experience at a National Referral Oncology Center in Mexico

Janeth Araujo Cardenas

Poster Presenter: Janeth Araujo Cardenas

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.